Source: International Congress 2018 – French Programme 2018: Part II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Migliori (Varese (VA), Italy). Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ?. International Congress 2018 – French Programme 2018: Part II

Member's Comments

No comment yet.

Related content which might interest you: Antiviral drugs: which and when? Source: Annual Congress 2006 - Influenza: from avian flu to pandemia? Year: 2006 Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Prospects for new compounds tiosemikarbazonami class to create drugs with antituberculosis activity Source: International Congress 2014 – Tuberculosis: diagnosis Year: 2014 Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe? Source: Eur Respir J 2016; 48: 1230-1233 Year: 2016 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Facts and perspectives in the development of new anti-TB drugs Source: Annual Congress 2008 - New insights into tuberculosis control Year: 2008 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 New anti-tuberculosis drugs for special populations: a difficult-to-address issue Source: Eur Respir J 2016; 48: 957-958 Year: 2016 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012 Atypical mycobacteriosis : new drugs, new strategies Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease Year: 2004 Would new drugs and regimens permit shorter TB treatments? Up to dateNovos fármacos e regimes permitiriam tratamentos mais curtos? Atualizar Source: International Congress 2017 – Spanish and Portuguese Programme 2017 Year: 2017 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013